viewTissue Regenix Group PLC

Tissue Regenix appoints new finance boss

Kirsten Lund has been promoted to finance director for her "invaluable" knowledge and understanding of the business, after nine years at the firm

Tissue Regenix Group PLC -
The maker of regenerative medical devices said it hopes to drive future growth with the appointment

Tissue Regenix Group (LON:TRX) appointed Kirsten Lund as its new finance director on Tuesday.

The regenerative medical devices group said that Lund has been promoted to finance director after nine years at the firm as financial controller, but will not be appointed to the board.

READ: Tissue Regenix confirms US$300,000 grant for San Antonio facility

She will take up with immediate effect the responsibilities of the chief financial officer, Mike Barker, who has resigned from his position for personal reasons and will leave the company at the end of November.

John Samuel, executive chairman, called Lund an “excellent asset to the management team”, saying that her “knowledge and understanding of the business is invaluable as we look to drive the future growth of the company”.

Chartered accountant Barker leaves the group after being appointed in August, and having served two previous stints as interim chief financial officer.

Quick facts: Tissue Regenix Group PLC

Price: 0.351 GBX

Market: AIM
Market Cap: £24.69 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...



Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

2 min read